Who
Richard I. Steinhart
Director
Company insider
Files Form 4 as: Director, Actinium Pharmaceuticals, Inc. (Delaware); Chief Financial Officer, BioXcel Therapeutics; Director, Atossa Therapeutics; Chief Financial Officer, Mela Sciences, Inc. /ny; Director, TG Therapeutics.
In numbers
- Trades disclosed
- 151
- Buys
- 6
- Sells
- 9
- Bought
- $21K
- Sold
- $380K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 30 Jan 2007
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —62,800 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —94,200 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —94,200 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —62,800 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —35 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —35 | filing |
| 20 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,4276,845 at $1.09 | filing |
| 20 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,4616,845 at $1.09 | filing |
| 12 May 2026filed 14 May 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —17,500 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
| 4 May 2026filed 22 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —17,500 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,000 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 1 May 2026filed 7 May 2026 | BioXcel TherapeuticsBiotechnology | SEC FORM 4 Code M | —9,000 | filing |
News
No headline names them, or the companies they trade most, lately.